# Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

> **NCT01579903** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 16 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** moroctocog alfa (AF-CC)
- **DRUG:** moroctocog alfa (AF-CC)

## Key facts

- **NCT ID:** NCT01579903
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579903, "Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01579903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*